Clinical Trials | August 06, 2025
AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Vasograin Plus represents a major advancement in the treatment of migraine
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
NewCo’s pipeline includes five investigational medicines
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Subscribe To Our Newsletter & Stay Updated
